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ABSTRACT Broad substrate speciﬁcity of human P-glycoprotein (ABCB1) is an essential feature of multidrug resistance.
Transport substrates of P-glycoprotein are mostly hydrophobic and many of them have net positive charge. These compounds
partition into the membrane. Utilizing the energy of ATP hydrolysis, P-glycoprotein is thought to take up substrates from the
cytoplasmic leaﬂet of the plasmamembrane and to transport them to the outside of the cell. We examined this model bymolecular
dynamics simulation of the lipid bilayer, in the presence of transport substrates together with an atomic resolution structural model
of P-glycoprotein. Taken together with previous electron paramagnetic resonance studies, the results suggest that most
transported drugs are concentrated near the surface zone of the inner leaﬂet of the plasma membrane. Here the drugs can easily
diffuse laterally into the drug-binding site of P-glycoprotein through an open cleft. It was concluded that the initial high-afﬁnity drug-
binding site was located in the interfacial surface area of P-glycoprotein in contact with the membrane interface. Based on these
results and our recent kinetic studies, a ‘‘solvation exchange’’ drug transport mechanism of P-glycoprotein is discussed. A
molecular basis for the improved colchicine transport efﬁciency by the much-studied colchicine-resistance G185Vmutant human
P-glycoprotein is also provided.
INTRODUCTION
Multidrug resistance (MDR) is a critical problem in cancer
chemotherapy. Overexpression of P-glycoprotein (ABCB1,
MDR1 gene product) on the plasma membrane is frequently
observed in drug-resistant cancer cells leading to the failure
of chemotherapy (1). P-glycoprotein also modulates drug
absorption, bioavailability, tissue disposition, and excretion
and plays an important role in compromising AIDS chemo-
therapy and other drug-treatable diseases (reviewed in 2–4).
P-glycoprotein transports various hydrophobic compounds
out of the cell by utilizing the energy of ATP hydrolysis (5).
The amino acid sequence and topology of P-glycoprotein
indicate that it is a member of one of the largest membrane
protein families, namely the ATP binding cassette transporter
family (ABC super family) (6). ABC transporters have two
highly conserved ATP-binding catalytic domains and two
relatively variable transmembrane domains that function
together as a unit. These proteins play central roles in solute
transport across various membranes. Transport substrates of
ABC transporters include sugars, amino acids, vitamins,
lipids, sterols, peptides, toxins, and drugs (7). A characteristic
feature of P-glycoprotein is its broad substrate speciﬁcity (8).
Typical transport substrates of P-glycoprotein are hydropho-
bic and positively charged molecules that can form hydrogen
bonds (9–11). In many cases, these substrates have aromatic
rings but this is not an absolute requirement. In general,
P-glycoprotein does not transport net negatively charged
compounds (reviewed in Seelig and Landwojtowicz (12)).
Within these broad criteria, there are no further structural
relationships between the diverse chemical compounds that
P-glycoprotein transports. Such a diversity of P-glycoprotein
substrates poses a signiﬁcant problem for clinical treatment.
Therefore, elucidating the mechanism of substrate recogni-
tion by P-glycoprotein is of great medical interest.
P-glycoprotein substrates generally partition to the lipid
bilayer due to their hydrophobicity. When photoactivated,
photoreactive drugs label the transmembrane domain of
P-glycoprotein, indicating that substrate binding sites are
located in the membrane region (13,14). In addition, muta-
tions in the transmembrane domains change the substrate
speciﬁcity (15,16). Interestingly, the apparent Km values of
P-glycoprotein drugs have a clear correlation with the
hydrophobicity of these drugs (12). Based on such studies,
Gottesman and colleagues postulated the ‘‘hydrophobic
vacuum cleaner model’’ (1). In this model, hydrophobic
drugs are partitioned into the inner leaﬂet of the plasma
membrane where P-glycoprotein takes these drugs from the
lipid bilayer and transports to the aqueous phase of the other
side of membrane. This model was supported by transport
experiments with ﬂuorescent drugs (17–20) and more
recently by EPR studies employing spin-labeled verapamil
(21). However, despite the extensive biochemical and ge-
netic studies, details of drug recognition by the P-glycopro-
tein remain obscure. A common theme emerging from the
studies discussed above was that the interaction of drugs
with the lipid bilayer was a primary determinant for sub-
strate recognition of P-glycoprotein. Consequently, substrate
SubmittedNovember 14, 2005, and accepted for publication January 4, 2006.
Address reprint requests to Marwan K. Al-Shawi, Dept. of Molecular
Physiology and Biological Physics, University of Virginia Health System,
PO Box 800736, Charlottesville, VA 22908-0736. Tel.: 434-243-8674;
Fax: 434-982-1616; E-mail: ma9a@virginia.edu.
Hiroshi Omote’s present address is Dept. of Membrane Biochemistry,
Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1
Tsushimanaka, Okayama 700-8520, Japan.
 2006 by the Biophysical Society
0006-3495/06/06/4046/14 $2.00 doi: 10.1529/biophysj.105.077743
4046 Biophysical Journal Volume 90 June 2006 4046–4059
binding by P-glycoprotein should be considered in two steps,
the initial partitioning of drugs to the lipid bilayer followed
by binding to transmembrane region of P-glycoprotein (21).
Recent progress in molecular dynamics (MD) simulations
allows the simulation and investigation of the interactions of
small molecules with the lipid bilayer (22–24). In this study,
we tested the interaction of P-glycoprotein transport sub-
strates with the lipid bilayer by molecular dynamics and ex-
plored possible drug-recognition sites by atomic detail
homology modeling of human P-glycoprotein.
MATERIALS AND METHODS
Molecular dynamics simulations
Topology and coordinates of each drug were generated by PRODRG (25).
For charged molecules, the charge distribution was calculated using
MOPAC (26). Charged rhodamine 123, daunorubicin, protonated verapa-
mil, and spin-labeled verapamil (SL-verapamil, (21)) were treated as having
a 11 charge and Hoechst 33342 was treated as having a 13 charge.
Coordinates and parameters for dipalmitoyl phosphatidylcholine (DPPC)
were obtained from previous reports (27,28). Simulations were run using the
GROMACS v3.14 with a modiﬁed GROMOS87 force ﬁeld, parameter set
ffgmx (29,30).
Energy minimized drug molecules were manually placed on the surface
area of the lipid bilayer. For positively charged drugs, chloride anions were
added to keep the net charge of the system neutral. To minimize the artifact
of a periodic boundary, the lipid bilayer was fully hydrated by simple point
of charge water molecules at a water/lipid ratio of 33 or larger (27). A typical
system contained 128 molecules of DPPC, 1 drug molecule, and ;4625
water molecules with initial dimensions of 6.42 3 6.44 3 7.50 nm. The
system temperature was set to 325 K, well above the transition temperature
of the DPPC bilayer. Systems were subjected to 1000 steps of steepest
descents energy minimization followed by 100 ps molecular dynamics. The
resultant coordinates were used for 10–20 ns molecular dynamics simula-
tions. These simulations were carried out in the NPT ensemble with constant
pressure (1 bar) for all three directions using a coupling constant of tP ¼ 1.0
ps. Temperatures of lipids, water, and drugs were controlled separately with
a temperature-coupling constant of tT ¼ 0.1 ps. All bond lengths were
constrained using LINCS (31). A twin-range cutoff of 0.9–1.8 nm was used
for Lennard-Jones (van der Waals) and long-range electrostatic interactions,
respectively. Integration step time was 2 fs and trajectories (coordinates and
velocities) were recorded each 20 ps. In this conﬁguration, the system was
stable for at least 20 ns. All simulations were carried out a minimum of two
times.
Homology modeling of human P-glycoprotein
Homology modeling of human P-glycoprotein was carried out using
MODELLER 6v3 (32) by a new reﬁned procedure of our previously
described method (33). Transmembrane regions and nucleotide binding
domains were modeled separately in an approach similar to that previously
reported for MsbA (34). Initially, sequences of Vibrio cholera MsbA
(residues 10–564), human P-glycoprotein N-terminal half (residues 34–
637), and C-terminal half (residues 694–1279) were aligned through
ClustalX (35). Alignment of transmembrane domains was veriﬁed by
secondary structure analysis (PHD (36) and PROF (37)) and then man-
ually adjusted by the location of gaps and aromatic residues. The crystal
structure of V. cholera lipid A transporter MsbA (Protein Data Bank
(PDB) ﬁle 1PF4) was used as a template structure for the transmembrane
domains (38). Missing parts of the crystal structure (residues 203–237 of
MsbA, and residues 250–284 and 893–927 of human P-glycoprotein) were
each modeled as a helix-loop-helix as predicted by PHD (Fig. 1). The
conformation of V. cholera MsbA nucleotide-binding domain was
different from other ABC proteins. In MsbA, the catalytic P-loop (Walker
A motif) was not aligned with other catalytic residues such as Asp-505,
Glu-506 of the Walker B motif (MsbA numbering), or the Q-loop.
This suggested that catalytic domain of this crystal structure was not in
an active form. Therefore, P-glycoprotein nucleotide binding domains
(residues 340–637 and 983–1280) were modeled using Salmonella
typhimurium histidine permease HisP coordinates (PDB ﬁle 1B0U) as a
template structure (39). Modeled P-glycoprotein nucleotide binding
domains (residues 391–637, 1034–1280) and transmembrane domains
(10–390, 695–1033) were assembled by ﬁtting to the corresponding re-
gions of the MsbA structure. The linker regions (P-glycoprotein residues
360–390 and 1014–1035) between transmembrane domains and nucleo-
tide binding domains did not ﬁt the MsbA structure. These regions were
modeled as a helix and a loop according to secondary structure prediction.
PROCHECK (40) was used to check for atom clashes, bond lengths,
adequate bond angles, and backbone dihedral stereochemistry. When
unfavorable conditions were encountered, molecular dynamics simulated
annealing was performed using MODELLER. The temperature was
increased from 150 to 1300 K in six steps with 300 iterations each for
equilibration followed by nine cooling steps to 300 K with 1000 iterations
each for equilibration. This intermediate model contained some atomic
clashes, particularly in the Walker B regions, that could not be resolved by
energy minimization alone. To overcome this, the nucleotide binding
domains (residues 340–637 and 983–1280) were remodeled into this
intermediate form using human TAP1 (41) as a template (PDB ﬁle 1JJ7).
Initially, there were still small atomic conﬂicts between the Walker B
regions. These conﬂicts disappeared after a few cycles of energy min-
imization as described above. The ﬁnal model had no atom clashes and
generated a Ramachandran plot (42) in which 98.7% of the backbone
angles were in allowed regions. Coordinates are available by request. It is
important to note that the ﬁnal structure recapitulated the ‘‘nucleotide
sandwich’’ dimer-interface seen in Escherichia coli BtuCD (43) (PDB ﬁle
1L7V) although this structure was not used in the modeling (see Fig. 2 B).
The BtuCD nucleotide dimer interface is believed to be a physiologically
relevant form (44).
Fig. 1 illustrates the location of structural elements and conserved
motifs in the primary sequence of human P-glycoprotein. The resultant
modeled structure is shown in Fig. 2. As discussed in Omote et al. (33) the
structural model generated was different from that of Seigneuret and
Garnier-Suillerot (45), which was in an open conformation. The model of
Fig. 2 was in a closed conformation and was similar to the structural
models of Stenham et al. (46) and more recently Pleban et al. (14). Both of
these later models demonstrated the presence of a central cavity as was
observed in Fig. 2. The nucleotide binding-site dimer interface (Fig. 2 B)
was similar to that of Shilling et al. (47). For a review of the dimer
interface see Higgins and Linton (48). The order of transmembrane helices
(TM) (Fig. 2 C) was 2, 3, 4, 1, 6, 5, 8, 9, 10, 7, 12, 11; counterclockwise
when viewed from the cytoplasm. Recent cross-linking experiments have
veriﬁed this order (49,50). This same order of TMs was also observed
in the recent x-ray crystal structure of S. typhimuriumMsbA (51). Overall,
the model presented in Fig. 2 is a consensus structural model that
is expected to be highly representative of the true structure of P-glyco-
protein.
Measurement of intrinsic drug transport
turnover numbers
The intrinsic turnover numbers for drug transport at pH 7.5 and 35C were
obtained for the transport of verapamil, spin-labeled verapamil, Hoechst
33342, colchicine, rhodamine 123, and daunorubicin by human P-glycopro-
tein reconstituted into ‘‘mixed lipid’’ proteoliposomes (52). The methods
employed are fully described in Omote et al. (33). Brieﬂy, P-glycoprotein
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turnover numbers were measured as a function of drug concentration, ATP
concentration, and seven temperatures by Pi production rates of ATP hy-
drolysis. For conditions of coupled drug transport, the intrinsic Vmax values at
saturating ligand concentrations were calculated by extrapolation of the
kinetic and thermodynamic data obtained to saturating drug and ATP
concentrations. The turnover number for the ﬂux through the coupled drug
transport cycle (52) was equated to the intrinsic drug transport rate of
P-glycoprotein.
FIGURE 1 Location of structural el-
ements and conserved motifs in the
primary sequence of human P-glyco-
protein. The primary sequence of hu-
man P-glycoprotein is shown with the
PHD predicted secondary structure (37)
where H indicates helical residues and
E indicates b-strand residues. Locations
of transmembrane residues (TM1–
TM12) are indicated by ribbon helices
and locations of intracellular domains
are indicated by shaded bars (ICD1–
ICD6) (based on Chang (38)). Con-
served nucleotide binding domain
(NBD) motifs Walker A, Q-loop, ABC
signature, and Walker B are indicated
by solid black bars.
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RESULTS
Drug and lipid bilayer interactions investigated
by molecular dynamics
In this study, dipalmitoyl phosphatidylcholine was chosen
because membrane bilayers with this lipid have been well
characterized by molecular dynamics studies (27). In
addition, P-glycoprotein is believed to be enriched in lipid
rafts containing saturated lipids (53). There were no sig-
niﬁcant drifts of pressure, temperature, and box size over the
10–20 ns simulations suggesting that the lipid bilayer was
well equilibrated. The mean distance between lipid phos-
phorous atoms of the two leaﬂets was 3.9 nm and the surface
area per lipid was 0.64 nm2. Values were slightly larger than
those reported previously (27) due to the higher temperature
employed here. We tested deprotonated verapamil, proton-
ated verapamil, Hoechst 33342, spin-labeled verapamil (SL-
verapamil, (21)), colchicine, charged and uncharged forms
of rhodamine 123, and daunorubicin, for drug-lipid interac-
tions. All of these drugs are good transport substrates of
P-glycoprotein for which kinetic and thermodynamic data
are available (52). The structures of these drugs are shown
in Fig. 3. Typical snapshots after 10 ns of simulation are
illustrated in Fig. 4 for deprotonated and protonated forms of
verapamil. Trajectory analysis of deprotonated verapamil
showed two different phases (Fig. 5, A and B). Until ;5 ns
deprotonated verapamil was located in the surface area of the
lipid bilayer, then suddenly it entered into the hydrocarbon
core of the lipid bilayer (Figs. 4 A and 5 A, z axis). Except for
the transition, the z axis position of verapamil was then
stable. On the other hand, movement parallel to the mem-
brane (lateral diffusion) was free until the end of the simu-
lation time course. Similar patterns were observed in multiple
simulation runs. This result indicates that deprotonated
verapamil has two different phases of lipid interaction and
there is an energetic barrier to enter the hydrophobic core of
the membrane. Flip-ﬂop of deprotonated verapamil was not
observed during the 20 ns time courses, suggesting there is
another energy barrier to cross to the other side of the bilayer.
Such a ﬂip-ﬂop is expected to occur in a much longer time
domain (54). However, portions of the verapamil molecules
were observed to cross the membrane median (Fig. 6 A). For
the other drugs simulated, entry deep inside the hydrocarbon
zone without surface interaction was not observed (Figs. 4 B,
5 B, and 6 B–F). For these drugs, vertical movement was
limited in the membrane (Z axis) after establishing stable
lipid interactions. On the other hand, lateral diffusion oc-
curred freely in the X and Y plane.
Atomic and molecular density distributions after estab-
lishment of stable drug-lipid interactions are summarized in
Fig. 6. The averaged equilibrium positions from the center of
the bilayer for the different drugs were as follows: depro-
tonated verpamil, 0.73 nm; protonated verapamil, 1.47 nm;
Hoechst 33342, 1.46 nm; SL-verapamil, 1.49 nm; colchi-
cine, 1.41 nm; uncharged rhodamine 123, 1.45 nm; charged
rhodamine 123, 2.03 nm; and charged daunorubicin, 2.08
nm. Clearly, the drugs prefer the surface or interfacial region
of the membrane except for deprotonated verapamil. In
general, the hydrophobic part of the drugs enters the
hydrocarbon zone of the lipid bilayer but the charged part
maintains interactions with the surface (Fig. 4 B). On en-
tering the hydrocarbon layer of the lipid bilayer, deproto-
nated verapamil lost all H-bonds (Fig. 5 C). In contrast, the
protonated form maintained H-bonds to water and lipid
headgroups throughout the simulation time (Fig. 5 D). The
protonated nitrogen of verapamil formed hydrogen bonds to
FIGURE 2 Atomic detail homology and energy mini-
mized model structure of human P-glycoprotein. This
model is a reﬁnement of our previous homology model
(33). The crystal structure coordinates of V. cholera lipid A
transporter MsbA (38) S. typhimurium histidine permease
HisP (39) and human TAP1 (41) were used (see Materials
and Methods). Atom conﬂicts were removed by simulated
annealing and the structure was energy minimized. One
rhodamine 123 molecule (illustrated by space-ﬁlling
model) is shown in the putative high-afﬁnity binding site
of the N-terminal half-molecule. See text for further
details. (A) A closed-structure conformation of the whole
protein and bound drug showing discussed structural
elements. (B) View of the nucleotide sites from the
cytoplasm. (C) View of the TMs from outside the cell,
illustrating the drug binding structures.
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oxygen atoms of carbonyl, phosphate, and glycerol moieties
of the lipid. Although the number of polar interactions with
the surface interfacial zone was different for each drug, sim-
ilar patterns were observed for the other cationic drugs (not
shown).
Drug recognition site of human P-glycoprotein
Bacterial lipid A transporters (MsbA) are members of the
ABC protein family and exhibit high homology to human
P-glycoprotein. Expression of MsbA in E. coli conferred
multidrug resistance and ethidium extrusion to the cells.
Additionally puriﬁed and reconstituted protein was shown to
bind drugs and to transport Hoechst 33342, suggesting that
MsbA works, to some extent, as a drug transporter (55).
Moreover, one member of the P-glycoprotein family, MDR3
(ABCB4), transports phosphatidylcholine (56). Given the
functional similarity and high degree of homology of E. coli
MsbA and P-glycoprotein (31% and 30% sequence identity
with the N- and C-terminal halves, respectively), we can
expect that they share a similar structure and mechanism. It
has been demonstrated that proteins with a sequence identity
greater than 25% have similar three-dimensional structures
(57). Recent crystal structures of E. coli and V. cholera
MsbA showed that it contained an internal large chamber
enclosed by the transmembrane domains from each half-
molecule. This chamber has enough space to bind lipid A
(38,58). A unique distribution of positive charges inside the
chamber insinuated the importance of charged residues in the
transmembrane region for substrate recognition of the neg-
atively charged lipid A. As the crystal structure of human
FIGURE 3 Chemical structuresofdrug
molecules used in molecular dynamics
simulations.
FIGURE 4 Snap shots from molecular dynamics simulations. Snapshots
of deprotonated verapamil (A) and protonated verapamil (B) were taken at
the end of 10 ns molecular dynamics simulations. Drugs are illustrated by
large space-ﬁlling models, water molecules by small ball models and lipids
by line models.
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P-glycoprotein is still not available, we examined the pos-
sible drug binding site of this protein based on a modiﬁed
version (Materials and Methods) of a homology modeled
structure (33) constructed using V. cholera MsbA (38), S.
typhimurium HisP (39), and human TAP1 (41).
P-glycoprotein favors positively charged amphipathic
molecules (see Introduction), which suggests the involve-
ment of acidic residues in drug binding. Interestingly, there
were no acidic residues in the chamber of the modeled
structure indicating cationic selectivity of P-glycoprotein is
not determined by this region (see Figs. 7 and 8). In MsbA
the chamber carries a net positive charge (38,58). In models
of P-glycoprotein the net charge of the chamber is weak and
may be slightly positive (Fig. 8). However, the outside
perimeter of the intracellular domain helices (ICD helices of
Fig. 2 A, located above the membrane in Fig. 7) has strong
positive charge densities (not shown). On the other hand,
there are well-conserved acidic residues in the surface zone
of the chamber and helix bundle composed of ICD helices 1,
3, 4, and 6 (Fig. 7, shaded labels; see also Fig. 1 for
alignments). These residues, D188, E353, E782, and D997
are close to the membrane surface and facing inside the ICD
bundle. Furthermore, these residues are accessible fromwithin
the putative drug-binding chamber. Thus, these residues are
in a good position to form electrostatic interactions with
positively charged drugs that enter the chamber. Since
cationic drugs are concentrated in the surface area of mem-
brane (Fig. 6), these residues may contribute to the positive
charge drug selectivity of P-glycoprotein. Recent data
obtained for E314 of LmrA (59), a homologous residue of
residues E353 and D997 of P-glycoprotein, are supportive of
this notion. In the same region, many other hydrophilic
residues can form H-bonds with drugs. These residues
include Q132, Q143, Q195, S196, T199, S228, K234, N296,
S309, Q347, S351, and N357 in the N-terminal half-
molecule (Fig. 7 A) and residues Q773, T776, T785, S831,
Q838, N839, N842, S880, K877, Q990, and S993 in the
C-terminal half-molecule (Fig. 7 B). Also, many aromatic
residues such as F135, W136, W232, Y310, F343 in the
N-terminal half (Fig. 7 A) and F777, F942, Y953, and F994
in the C-terminal half (Fig. 7 B) were found in the chamber
near these acidic residues. Side chains of aromatic residues
contribute to drug binding through interaction with the
aromatic rings of drugs (60). These types of interactions have
been observed in the AcrB multidrug efﬂux pump of E. coli
(61). Such aromatic residues are not conserved in MsbA. The
many polar residues scattered throughout the putative drug-
binding chamber (Fig. 7) serve to form hydrogen bonds with
drugs and water. Such hydrophilicity of the chamber appears
to be a critical feature of P-glycoprotein functionality as
discussed later. The interaction of drugs with P-glycoprotein
through hydrogen-bond donor side chains and clusters of
amino acids with p-electron systems has been previously
proposed (62).
To test the proposed involvement of the chamber residues
discussed above in drug binding, we performed MD sim-
ulations using the modeled structure generated. GROMACS
v3.14 was used for simulations as previously discussed.
Water molecules were introduced into the putative drug-
binding chamber by the GENBOX function. A single mol-
ecule of rhodamine 123 was manually introduced into the
chamber and MD simulations were run. An equilibrium
drug-binding position was found. Rhodamine 123 xanthenyl-
moiety was found to interact with the aromatic residues
W136 and F200 through van der Waals interactions. Sim-
ilarly, the benzoic acid moiety interacted with residue F343
through van der Waals interactions. Residue K234 formed an
H-bond to the carbonyl of the benzoic acid methyl ester.
Residue M192 and Q195 were also involved in forming the
binding site. Additionally the rhodamine 123 molecule
oscillated forming from zero to two transient H-bonds with
FIGURE 5 Trajectory and hydrogen bond formation of verapamil in the
membrane bilayer. Molecular dynamics simulations of P-glycoprotein
transport drugs entering a DPPC bilayer were performed as detailed in
Materials and Methods. Centers of mass of deprotonated verapamil and
protonated verapamil were calculated and plotted against the elapsed
simulation time. Distances for each axis were measured from the corner of
the simulation box. X and Y axes are parallel to the plane of the membrane
and the Z axis is perpendicular to the lipid bilayer. The center of the lipid
bilayer in the Z axis is 3.74 nm. (A) Illustrates the change in coordinate
distances for deprotonated verapamil. (B) Illustrates the change in coordinate
distances for protonated verapamil. Hydrogen bonds formed between
verapamil and water and lipid headgroups were also determined during the
simulation time course. Number of hydrogen bonds formed is plotted as a
function of time for deprotonated verapamil (C) and protonated verapamil
(D). In panel C, after 5.5 ns, deprotonated verapamil fully enters the
hydrocarbon core of the bilayer and abolishes all hydrogen bonding from
then on (zero hydrogen bonds formed).
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residues Q195, S196, T199, L227 (main-chain carbonyl),
and S228. Similar interactions were observed by extensive
molecular dynamics simulations when the modeled
P-glycoprotein was inserted into a fully hydrated POPC
bilayer containing 448 POPC lipids in the presence of 100
mM NaCl (H. Omote and M. K. Al-Shawi, unpublished
data). These results conﬁrm the importance of the aromatic
and polar chamber residues in drug binding and indicate a
degree of ﬂexibility in drug binding by P-glycoprotein. In the
simulations it was found that the average distances from the
center of the rhodamine 123 molecule to the Walker A
conserved lysine e-amino nitrogen atoms were 46 A˚ and 45
A˚ for residues K536 and K1076, respectively. These lysine
e-amino nitrogen atoms were only 10.5 A˚ apart after rhoda-
mine 123 binding. Sharom and colleagues (63,64) measured
somewhat smaller distances of 38 A˚, by a ﬂuorescence res-
onance energy transfer (FRET) approach, from the nucleo-
tide sites to bound rhodamine 123 (ﬂuorescence donor). It is
likely that the large ﬂuorescence acceptor moieties (7-cholo-
4-nitorbenz-2-oxa 1,2-diazole), covalently attached to the
conserved C428 and C1071 of the Walker A sequence of
Chinese hamster P-glycoprotein, account for the apparent
shorter distances to the rhodamine 123 binding site.
Contribution of hydrogen bonds to drug
speciﬁcity and transport turnover rates
For charged drug species, MD simulations showed that
potential hydrogen bonds could not be satisﬁed within the
hydrocarbon layer of the bilayer (Figs. 4 and 5). Thus, it
appears that one function of P-glycoprotein is to provide
alternative hydrogen bonds to drugs. P-glycoprotein must
pick up the drugs at the membrane/water interface where
they were located (Fig. 6, B–F). Hence, as discussed above,
P-glycoprotein must have some hydrophilic residues to
interact with drugs near the lipid surface for hydrogen bond
exchange. To study this involvement of H-bond donation by
P-glycoprotein, we plotted a free energy relationship be-
tween the experimentally determined intrinsic drug transport
rate and the MD calculated number of H-bonds formed with
the drug (Fig. 9). The log value of the time-averaged number
of H-bonds formed by a drug is directly proportional to the
potential H-bonding interaction-energy available.
There was a direct linear free energy relationship between
the potential of the drug to form H-bonds and the intrinsic
drug transport rate of P-glycoprotein (Fig. 9). For drugs with
a high H-bonding potential the intrinsic transport rate was
FIGURE 6 Distribution density proﬁles of
drugs across the lipid bilayer. Distribution
density proﬁles relative to maximum distribu-
tion values of drugs, water and lipid atoms were
plotted against the Z axis position from the
center of the membrane. Positive Z axis values
represent distances from the center of the
bilayer toward the cytoplasm whereas negative
values are distances toward the outside of the
cell. Averaged densities were taken from MD
trajectories after reaching stable equilibrium
positions (7–10 ns averaged). (A) Deprotonated
verapamil; (B) protonated verapamil; (C)
Hoechst 33342; (D) SL-verapamil (colchicine
very similar, not shown); (E) uncharged rho-
damine 123; (F) charged daunorubicin (charged
rhodamine superimposable). Distribution density
lines are: thick solid lines with hatched areas,
drug; solid lines, water; dotted lines, phospho-
rous atoms of DPPC; dashed lines, nitrogen
atoms of DPPC.
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slow (e.g., daunorubicin). Whereas for drugs with a low
H-bonding potential the intrinsic drug transport rate was fast
(e.g., SL-verapamil). As discussed later, the ﬂipping of a
drug in P-glycoprotein’s drug-binding chamber becomes
harder with more H-bonds that need to be broken and
reformed. This inverse relationship between drug H-bonding
potential and turnover rate of P-glycoprotein has been pre-
viously observed (12,65).
Wild-type (WT) P-glycoprotein behaved anomalously by
transporting colchicine too slowly relative to its H-bonding
potential. The G185V mutation suppresses this effect by
increasing the intrinsic rate of transport to the expected one
(Fig. 9). It should be emphasized that G185V P-glycoprotein
does not change the intrinsic drug transport rate or drug
binding characteristics of all drugs but only a limited subset
such as colchicine and etoposide (33). This suggests that a
speciﬁc colchicine and etoposide drug-binding site has been
altered by mutation and not the other drug-binding sites, and
implies the existence of multiple chemically distinct drug-
binding sites on P-glycoprotein. Thus, the G185V mutation
distorts the binding site for colchicine while leaving binding
sites of other drugs intact. Binding of colchicine to WT and
G185V P-glycoproteins were characterized by van’t Hoff
analysis by methods previously described (52). For WT
P-glycoprotein the thermodynamic parameters DH, TDS,
and DG of colchicine binding at 35C and pH 7.5 were
125.7, 144.0, and 18.3 kJ mol1, respectively. Thus, the
net driving force for colchicine binding to WT protein was
through hydrophobic interactions (favorable entropy term).
The corresponding values for colchicine binding to G185V
P-glycoprotein were 191.4, 176.9, and 14.5 kJ mol1,
respectively. Here the net driving force for colchicine
binding to G185V P-glycoprotein was through favorable
noncovalent interactions (H-bonds) compensated somewhat
by a large unfavorable entropy term. Such net favorable
noncovalent interactions compensated by an unfavorable en-
tropy term have been previously characterized for verapamil
FIGURE 8 Surface potential distribution of modeled human P-glycopro-
tein. A molecular surface of modeled human P-glycoprotein showing the
electrostatic potential distribution is shown in the same orientation as Fig. 7.
The ﬁgure was prepared with WebLab ViewerPro (Accelrys, San Diego,
CA) with red and blue indicating negative and positive charge, respectively.
FIGURE 7 Postulated P-glycopro-
tein residues that contribute to initial
drug binding. A structural model of
human P-glycoprotein is shown based
on homology modeling (Fig. 2). See
Materials and Methods for modeling
details. Amino terminal and carboxyl
terminal halves of P-glycoprotein mol-
ecules are illustrated in left and right
side panels, respectively. Both half-
molecules are viewed parallel to the
plane of the membrane from the center
of the putative drug chamber side as
illustrated by the schematic inset. A
whole P-glycoprotein molecule can be
assembled by rotating one of the two
halves by 180 normal to the plane of
the membrane and bringing the two
halves together to form the putative
drug binding chamber. The membrane
zone is shown as green bands with a
dotted line indicating the center of the
bilayer. Polar and aromatic residues
inside the chamber are illustrated by
space ﬁlling models. Candidate resi-
dues that contribute to initial drug
binding are labeled by arrows. Nega-
tively charged residues have shaded
labels. Structure illustrations were pre-
pared by Molscript (89).
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binding to WT P-glycoprotein (52). The results above
indicate that, in WT P-glycoprotein, colchicine was binding
too tightly to the ground state through speciﬁc nonpolar van
der Waals interactions leading to a decreased transport rate.
The G185V mutation modiﬁed the colchicine binding site in
such a fashion as to reduce the contribution of nonpolar
interactions. Polar interactions were now dominant and the
overall colchicine afﬁnity was reduced. These factors im-
prove the colchicine transport rate and coupling efﬁciency of
the G185V mutation as previously described (33).
DISCUSSION
The most remarkable features of P-glycoprotein are its broad
transport-substrate speciﬁcity and the existence of basal
ATPase activity in the absence of drug substrates (52). These
features suggest that bond interactions between drugs and
P-glycoprotein required to trigger the ATPase reaction ex-
hibit a high degree of ﬂexibility. The observed broad drug-
speciﬁcity is an essential component of P-glycoprotein’s
function as a multidrug resistance pump. Thus, a good under-
standing of substrate recognition by P-glycoprotein is of pri-
mary interest in drug development for the treatment of cancer,
AIDS, and other diseases inﬂuenced by P-glycoprotein.
Drug and membrane interactions
Most P-glycoprotein substrates are hydrophobic and are
concentrated in the membrane. Even in the case of SL-
verapamil, a relatively hydrophilic drug, the concentration in
the vesicle membranes was 11 times higher than the con-
centration in the bulk water phase (21). A clear relationship
between the partition coefﬁcient of drugs and the apparent
Km for drugs by P-glycoprotein exists (12,66). Such results
indicate that drug binding to the lipid bilayer is an initial step
of drug recognition by P-glycoprotein. In this regard, the
mode of interaction of drugs with the lipid bilayer is an
important property to understand. Results of MD simulations
performed in this study showed that cationic P-glycoprotein
drugs were concentrated in the surface zone of the membrane
(Fig. 6). Hydrophobic parts of the drug molecules were able
to enter the hydrocarbon core of the membrane, but the drugs
simultaneously retained polar interactions with water and
lipid headgroups (see Results). Thus, polar interactions of
drugs and lipid headgroups need to be considered.
Recently, we described a new spin-labeled verapamil,
which was an excellent transport substrate of P-glycoprotein,
and was relatively hydrophilic due to a ﬁxed positive charge
(21). Partition coefﬁcients of SL-verapamil between water and
olive oil showed that it was 120-fold more hydrophilic than
verapamil. Despite such hydrophilicity, P-glycoprotein has a
higher afﬁnity and transport rate for SL-verapamil than for
verapamil. According to the classical ‘‘hydrophobic vacuum
cleaner model’’ (1), a hydrophilic molecule is expected to have
a lower afﬁnity to P-glycoprotein. The high apparent afﬁnity of
SL-verapamil for P-glycoprotein seems to violate this rule. A
likely explanation of this apparent discrepancy is that the true
substrate of P-glycoprotein is the protonated form of verapamil
that is taken up from the surface zone (Fig. 6 B). In MD
simulations, protonated verapamil was located near the surface
region of membrane due to the polar interaction with lipid
headgroups and water (Figs. 4 B and 6 B). The results of Fig. 9
conﬁrm that protonated verapamil is the transported entity.
SL-verapamil never fully enters the hydrophobic core of
the membrane (Fig. 6 D). In agreement with this, doxoru-
bicin, another cationic P-glycoprotein substrate was reported
as being located in the surface area of bilayers by ﬂuores-
cence quenching experiments (67). The predominant species
of rhodamine 123 is a protonated form, since the estimated
pKa is 11 (68,69). In our simulations, protonated rhodamine
123 was located near the surface region of membrane as
were the other cationic drugs (Fig. 6). This suggested that
P-glycoprotein should take up transport substrates from near
the surface region of the membrane. Drugs are then free to
diffuse laterally into the drug-binding chamber of P-glyco-
protein (Fig. 7, A and B). The crystal structures of MsbA had
a chamber that was open to the inner leaﬂet of the plasma
membrane and further supports this notion (51,58). In our
homology model, there are two obvious drug entry clefts at
the correct height relative to the inner leaﬂet of the bilayer
(Fig. 2 A, front and back; Figs. 7 and 8, insets). These drug
entry clefts are similar but not identical to the drug entry
‘‘gates’’ proposed by Loo and Clarke (70). A similar cleft
opening was observed in the two-dimensional crystal of
P-glycoprotein (71).
FIGURE 9 Drug hydrogen bond formation correlates with P-glycoprotein
drug transport activity. The log of experimentally determined intrinsic drug
transport rates was plotted against the log of MD simulated time-averaged
number of H-bonds formed between the drug and the lipids at equilibrium. For
drug transport activity assays, pure human P-glycoprotein reconstituted in
‘‘mixed lipid’’ proteoliposomeswas assayed at 35Cand pH7.5 (seeMaterials
and Methods section for details). The line plotted was a linear regression
ﬁt to the data excluding the colchicine interaction with wild-type (WT)
P-glycoprotein (open symbol). The linear free energy relationship was char-
acterizedbya slopeof1.018, an intercept of 1.063, andanR2 valueof 0.9814.
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The uncharged form of verapamil easily entered the
hydrocarbon core of the lipid bilayer and abolished all polar
interactions with the surface (Figs. 4 A, 5, A and C, and 6 A).
On the other hand, the protonated form of verapamil (Figs. 4
B, 5, B and D, and 6 B) and SL-verapamil did not (Fig. 6 D).
These results agree with the fact that the activation energy of
dehydration is the primary determinant in passive membrane
permeation (23). Hence the very large hydration energy of
ﬁxed-charge molecules (72) is too large to overcome for
passive permeation through the membrane. This explains
why the ﬁxed positively charged SL-verapamil did not
permeate the bilayer by ﬂip-ﬂopping in transport studies
(21). A lipid bilayer is composed from well-ordered layers of
different physical properties (73). To passively cross the
membrane, a particle must pass through two highly charged
headgroup layers, two hydrophobic layers near the membrane
surfaces and through the hydrophobic tail zone (hydrophobic
core). However, the physical properties of the drug-binding
chamber are totally different from that of the lipid bilayer.
The existence of both polar and hydrophobic residues inside
the drug-binding chamber allows sequential drug dehydra-
tion, solvation, and rehydration to promote passage across
the membrane by the ‘‘solvation exchange mechanism’’ de-
scribed later. In this article, we use the terms hydration/
dehydration to specify solvation/desolvation of the drug by
water molecules. The terms solvation/desolvation alone
imply interaction of the drug with any solvent that surrounds
it, including the drug binding chamber of P-glycoprotein.
Drug binding to P-glycoprotein
Although P-glycoprotein can transport neutral drugs, it
prefers positively charged compounds (Introduction). This
suggests the presence of negatively charged residues near the
drug-binding site. Based on the mutational and cross-linking
studies, drug-binding sites are believed to be located in the
transmembrane domain. However, there are no acidic residues
in the middle of the drug-binding chamber of P-glycoprotein
(Figs. 7 and 8). We proposed above that P-glycoprotein picks
up substrates from the interfacial surface zone of the mem-
brane. In agreement with this, there are four conserved acidic
residues, namely D188, E353, E782, and D997 located in the
surface zone within ICD helices (Figs. 7 and 8; see also Figs.
1 and 2). Similar acidic residues have been identiﬁed in the
transport of cationic substrates in other drug resistance
transporters (59,61,74–79). In P-glycoprotein, these acidic
residues are close to the membrane surface and are accessible
from within the chamber. They are also close to the drug
entry clefts. Surrounding these residues are many polar and
aromatic residues that may be necessary for drug interactions
(Fig. 7). When drugs present at the membrane surface diffuse
laterally into the drug binding chamber of P-glycoprotein,
these acidic residues can provide the observed cation pref-
erence. It is in this zone that the initial interaction of
P-glycoprotein and drugs occurs.
The involvement of ICD helices in initial drug binding is
very important in the active transport mechanism. In the
crystal structure of MsbA, ICD1 interacts with the Q-loop of
N-terminal nucleotide binding domain (58). This Q-loop has
a conserved glutamine residue that is thought to bind to a
catalytic Mg21 ion and a catalytic water molecule in some
ABC proteins (80). In mouse P-glycoprotein, it has been
shown that the primary role of the Q-loop glutamines is in
interdomain signal communication between catalytic sites
and drug-binding sites (81). A critical role of Q-loop and
ICD1 helix interactions for conformational change trans-
mission between the catalytic site and transmembrane
domain was previously proposed (43). Binding of drugs at
the ICD/transmembrane helices interface would lead to
reorganization of the ICD helices and thus activate catalysis
through ICD/Q-loop interactions. Similarly, ATP hydrolysis
would induce the reorganization of the ICD helices coupled
to the reorganization of the transmembrane helices to initiate
the transport process. Recently, we found that G185 to valine
mutation at the interface of ICD1 and TM3 altered the energy
coupling of colchicine transport (33). In Results and Fig. 9
we demonstrate that G185V P-glycoprotein interacts with
colchicine in a manner that removes an overabundance of
nonpolar van der Waals interactions while satisfying the avail-
able H-bond acceptors. This is the molecular basis for the
observed improved energy coupling and transport of col-
chicine. Thus, substitution of a low ﬂexiblity valine for the
highly ﬂexible glycine disturbs the reorganization of ICD
and transmembrane helices such that the binding-site for
colchicine is constrained in a more favorable conformation
for colchicine binding. Loo and Clarke reported rotation
of helices 6 and 12 by ATP hydrolysis based on the cross-
linking experiments (82). Because TM6 and TM12 are con-
nected to ICD helices 3 and 6, respectively (Fig. 1), rotation
of these transmembrane helices (as seen by Rothnie et al.
(83)) inescapably indicates rotation of ICD helices 3 and 6.
The postulated conserved drug interacting residues D353
and D997 are located in ICD3 and ICD6. As discussed pre-
viously, these residues may interact with positively charged
drugs and any rotation of ICD helices would break such
interactions. In addition, helix rotation allows breaking of
hydrogen bonds between drug and polar residues such as
S351 and Q347. Other ICDs and transmembrane helices, as
well as ICD3, ICD6, TM6, and TM12, may rotate and break
hydrogen and charged bonds between drugs and P-glyco-
protein. Because such interactions tether the hydrophilic parts
of the drug to the membrane interface zone of P-glycoprotein,
breaking of these bonds could initiate ﬂipping of drugs
leading to eventually transport drugs to the other side of the
membrane.
Solvation exchange mechanism
The most energetically costly step of membrane permeation
of a polar particle is dehydration (23). For charged
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molecules, the dehydration energy required is too high to
overcome (72). For instance, the hydration energy of the
charged form of methylamine was reported as ;280 kJ
mol1. In the case of the KcsA potassium channel, a potas-
sium ion in the selectivity ﬁlter was coordinated with eight
carbonyl oxygens and two waters to minimize the hydration
energy difference (84). The small hydration-energy differ-
ence of potassium ions between the water phase and the
selectivity ﬁlter was an essential factor for the potassium
channel functionality. P-glycoprotein must have a similar
mechanism to transport polar and charged drugs. Based on
these facts, we hypothesize that P-glycoprotein works as a
hydration exchanger. In this mechanism, polar interactions
of drugs with lipid headgroups or water are replaced by
hydrogen bonds of polar side chains in the chamber and ICD
helices (Fig. 10). Limited access of water and lipid headgroups
to the drug binding sites facilitates the replacement of
the hydration shell around the drugs by hydrogen bonds to
P-glycoprotein. As discussed above, ATP hydrolysis rotates
ICD and transmembrane helices to break hydrogen and
charged bonds between drug and protein (Fig. 10 C). In
addition to bonds breaking, the chamber cleft, open to the
inner leaﬂet of plasma membrane, should be closed (Fig. 10
C). Further helix rotations create an open pore to other side
of the membrane (Fig. 10 D). Part of the energy used in
breaking drug to protein bonds would be compensated by
newly formed favorable interactions with other polar resi-
dues and water inside the drug-binding chamber. Once the
protein to drug H-bonds are disrupted, the previously
interfacial region tethered drug will initiate ﬂipping as it
searches for new bonding partners (Fig. 10, B–C). This
movement is facilitated by the presence of hydrophilic
residues (Fig. 7) and of water molecules in the drug-binding
chamber to allow transient compensating hydrogen bonds to
form. Fluorescent maleimide accessibility tests of the drug-
binding chamber of the bacterial multidrug transporter, LmrA,
suggested an aqueous ﬁlled chamber (85). The high content
of polar residues in the drug-binding chamber of P-glyco-
protein (Fig. 7) suggests a similar aqueous ﬁlled chamber. It
has been demonstrated that P-glycoprotein drug-binding
chamber is accessible to water during the transport cycle
(86). Brownian motion can then drive the drugs across the
FIGURE 10 Solvation exchange mechanism of drug transport by P-glycoprotein. A postulated mechanism of drug transport by P-glycoprotein is illustrated.
(A) A drug molecule is in equilibrium between the aqueous phase and the lipid bilayer. Due to hydrophobicity, drugs partition to the inner leaﬂet of the plasma
membrane. Drugs maintain contact with water and lipid headgroups through polar interactions to the polar parts of the drug. (B) The drug molecule can laterally
diffuse to the inside of the drug-binding chamber and bind to the drug-binding site. Part of the hydration shell of the drug is replaced by the polar residues in the
intracellular domain helices (ICD helices) and the upper part of the drug-binding chamber. The hydrophobic part of the drug is adsorbed by hydrophobic
residues in the chamber (hatched areas) through van der Waals interactions. (C) ATP hydrolysis closes the entry cleft and rotates helices located in the ICD and
chamber domains and destroys electrostatic interactions and hydrogen bonds between the polar part of the drug and P-glycoprotein (dotted arrow). Loss of
polar interactions that tether the polar part of the drug to the surface zone initiates ﬂipping of drug (solid arrows). Hydrophilic residues scattered inside of the
putative drug-binding chamber, and water molecules, may form transient hydrogen bonds to the drug aiding in the ﬂipping process. (D) ATP hydrolysis also
opens an exit through which water access is available. (E) Later favorable hydrophobic interactions to the drug are removed (dotted arrow) and more water
enters the chamber. Drug is thus forcibly rehydrated and partitioned to the water phase allowing diffusion to the extracellular aqueous space (solid arrow). This
large unfavorable utilization of energy is compensated by large favorable interactions formed in other parts of P-glycoprotein by the same helix rotating events.
See text for further details.
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chamber to the other side. During this migration, hydropho-
bic residues scattered throughout the inside of the drug-
binding chamber would maintain nonpolar interactions with
the hydrophobic part of the drug. Moving the drug across the
drug binding chamber is thus likely an isoenergetic process
(from the perspective of the drug’s chemical potential).
An important ﬁnding by Seelig and Landwojtowicz (12)
was that there was an inverse relationship between the air-
water partition coefﬁcient of a drug (Kaw; which is highly
correlated with the corresponding lipid-water partition coef-
ﬁcient) and the apparent Michaelis-Menten complex (KDm)
such that KDm3Kaw;1. In other words, the exchange of
drugs between the lipid and P-glycoprotein drug-binding
sites was approximately isoenergetic. Speciﬁcity and trans-
port rates were dependent on speciﬁc drug-protein bond
interactions being formed (12,52). These facts support the
model proposed above. Furthermore, in the overall energy
balance of P-glycoprotein, we previously demonstrated that
there was adequate energy generated by the hydrolysis of a
single ATP molecule to forcibly rehydrate a typical transport
substrate that was bound (52). This is so because the drug is
not fully dehydrated but is ‘‘solvated’’ by the protein. We
also demonstrated that drug transport had high activation
energies. Drug transport was facilitated by large entropic
compensation of unfavorable enthalpic terms indicating a
high degree of bond reordering and compensation. Further-
more, we demonstrated that different drugs form different
types of bond interactions with P-glycoprotein during trans-
port. In the movement of drugs across the protein, we also
demonstrated that those drugs that required a high degree of
bond reformation and compensation in their transport were
more difﬁcult for P-glycoprotein to transport (33,52). This
transport difﬁculty was manifested by lower intrinsic trans-
port turnover rates as well as lower overall thermodynamic
efﬁciency. This inverse relationship between bond formation
and rate of drug transport was also observed in Fig. 9 in this
study. Such obstacles to transport could be suppressed by
changing the local structure of P-glycoprotein by mutation
to improve coupling efﬁciency of particular drugs through
modiﬁed drug interactions. This was the case for the im-
proved transport of colchicine by the G185V mutation (33)
(Fig. 9). Utilizing puriﬁed P-glycoprotein reconstituted in
deﬁned proteoliposomes, we unequivocally demonstrated
net active transport (‘‘uphill transport’’) of drugs (21). In the
catalytic cycle, Pi release precedes drug release, which is
followed by ADP release (87). Approximately 20 kJ mol1
of nucleotide-binding energy is still stored in the complex
after the dissociation of Pi and drug. Finally, we demon-
strated that the overall rate-limiting step of P-glycoprotein,
during transport, was a carrier reorientation step (52). These
facts, taken together with the previous discussion and results
presented in this article, lead us to suggest that the last step of
drug transport (Fig. 10 E) entails further helix rotating
events. It is the ﬁnal step of drug release that would likely
require an energy input. These helix rotations remove fa-
vorable hydrophobic interactions to the drug while allowing
more water to enter the chamber. P-glycoprotein now adopts
the ‘‘low-afﬁnity drug-unloading’’ conformation (33,52).
Drugs are forcibly rehydrated to aid in their partitioning into
the extracellular aqueous medium. It is thus likely that
P-glycoprotein pumps out water as it pumps out substrates, as
was originally suggested by Zeuthen and Stein (88). Overall,
the net energy gain by the transported drug would be sup-
plied by the energy of ATP hydrolysis through helix rotation
events. The large unfavorable utilization of energy is com-
pensated to some extent by large favorable interactions
formed in other parts of P-glycoprotein by these same helix-
rotating events. With the dissociation of ADP, the protein
relaxes to its ground state.
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